BAI Announces 2021 Global Innovation Award Finalists
9.11.2021 15:30:00 EET | Business Wire | Press release
BAI announced the finalists for the 11th Annual 2021 BAI Global Innovation Awards, the industry’s prestigious awards program that celebrates new and innovative solutions in the financial services industry worldwide. The 2021 BAI Global Innovation Awards finalists are:
Innovation in Compliance and Risk Management
- Emirates NBD Bank, United Arab Emirates: Transforming the Anti-Money Laundering Framework
- Hummingbird, United States: Hummingbird Platform
- UnionBank of the Philippines, Philippines: Credit Card Fraud Detection Model
Innovation in Consumer Product and Services
- Commonwealth Bank of Australia, Australia: CommBank Benefits Finder
- FNB Insurance, South Africa: Future Family Benefit on Critical Illness
- ICICI Bank, India: IntelliCollect – AI powered Contactless Collection
- PNC Financial Services Group, United States: Low Cash Mode
- Yapı Kredi, Turkey: My Car+: Everything about your vehicle
Innovation in Digital Transformation
- AVIVA POLSKA, Poland: eInsurance Digital Omnichannel Life Insurance Application Journey
- Bank of America, United States: Bank of America Mobile Banking Super App
- Deutsche Bank, Germany: Deutsche Bank API Program Embedded Finance Initiative
- OneConnect Smart Technology Co., LTD, China: Global Markets Digital Lab in Abu Dhabi
- SolarisBank, Netherlands: Banking as a Service
Innovation in Human Capital
- KeyBank, United States: Remote Intern Program
- Payactiv, United States: Livelihood Employee Experience Platform
- Royal Credit Union, United States: Employee Learning Experience
Innovation in Environmental, Social and Governance (ESG)
- Bank of Montreal, Canada: BMO Give & Go
- BMO Harris Bank, United States: BMO for Black and Latinx Businesses
- Citizens Financial Group, United States: Citizens Green Deposits
- imagin, Spain: imagin: A Community with a Positive Impact
- Lufax Holding Ltd., China: Farmers’ Assistance Fund
- Wintrust Financial Corporation, United States: Wintrust Paycheck Protection Program (PPP) Resource Centers
Innovation in Internal Process
- Alior Bank, Poland: InfoNina, virtual assistant
- ICICI Bank, India: Pre-Delinquency Management
- Israel Discount Bank, Israel: POPCORN - An Innovative Customer Listening Model
- PKO Bank Polski, Poland: Road to Paperless Banking Empowered by Blockchain Technology
- PZU SA, South Africa: AI Assistant in Claims (Field Inspection)
Innovation in Small Business Product & Services
- HSBC UK, United Kingdom: HSBC Kinetic, Mobile Banking Service
- Lufax Holding Ltd., China: Lufax "Xingyun" Smart Loan Solution
- Ping An OneConnect Bank Limited, Hong Kong: “PAOB SME" Mobile Application
- Santander Bank, N.A., United States: Santander Treasury Fusion for Where You Do Business
- Tribal Credit, United States: Tribal Credit Tools
The winners will be announced in December 2021. To learn more please visit BAI Global Innovation Awards.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005488/en/
Contact information
Holly Hughes
BAI, Chicago
hhughes@bai.org
+1 (312) 683-2305
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom